Clinical Trial Update: A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008) [Phase 2]

View source ↗

Summary

Phase II trial of MK0457 in T315I-mutant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• MK-0457

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Leukemia | Phase 2 | Status: TERMINATED